{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T18:10:11Z","timestamp":1767204611432,"version":"build-2238731810"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Prader\u2013Willi Syndrome (PWS) is a rare genetic condition, which affects one in 25,000 births and results in various phenotypes. It leads to a wide range of metabolic and endocrine disorders including growth delay, hypogonadism, narcolepsy, lack of satiety and compulsive eating, associated with mild to moderate cognitive impairment. Prognosis is especially determined by the complications of obesity (diabetes, cardiorespiratory diseases) and by severe behavioral disorders marked by impulsivity and compulsion. This heterogeneous clinical picture may lead to mis- or delayed diagnosis of comorbidities. Moreover, when diagnosis is made, treatment remains limited, with high interindividual differences in drug response. This may be due to the underlying genetic variability of the syndrome, which can involve several different genetic mutations, notably deletion or uniparental disomy (UPD) in a region of chromosome 15. Here, we propose to determine whether subjects with PWS differ for clinical phenotype and treatment response depending on the underlying genetic anomaly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively included all 24 PWS patients who were referred to the Reference Center for Rare Psychiatric Disorders (GHU Paris Psychiatrie and Neurosciences) between November 2018 and July 2022, with either deletion (\n                      <jats:italic>N<\/jats:italic>\n                      = 8) or disomy (\n                      <jats:italic>N<\/jats:italic>\n                      = 16). The following socio-demographic and clinical characteristics were recorded: age, sex, psychiatric and non-psychiatric symptoms, the type of genetic defect, medication and treatment response to topiramate, which was evaluated in terms of eating compulsions and impulsive behaviors. We compared topiramate treatment doses and responses between PWS with deletion and those with disomy. Non-parametric tests were used with random permutations for\n                      <jats:italic>p<\/jats:italic>\n                      -value and bootstrap 95% confidence interval computations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>First, we found that disomy was associated with a more severe clinical phenotype than deletion. Second, we observed that topiramate was less effective and less tolerated in disomy, compared to deletion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These results suggest that a pharmacogenomic-based approach may be relevant for the treatment of compulsions in PWS, thus highlighting the importance of personalized medicine for such complex heterogeneous disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnins.2023.1126970","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T01:42:00Z","timestamp":1675647720000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Prader\u2013Willi syndrome: Symptoms and topiramate response in light of genetics"],"prefix":"10.3389","volume":"17","author":[{"given":"C\u00e9cile","family":"Louveau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimi-Caterina","family":"Turtulici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ang\u00e8le","family":"Consoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Poitou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muriel","family":"Coupaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Odile","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Chaumette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Iftimovici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S2215-0366(18)30009-9","article-title":"\u2018Mechanistic Insights into the genetics of affective psychosis from prader-willi syndrome\u2019.","volume":"5","author":"Aman","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0312-z","article-title":"\u2018Evaluation of the hypothalamic-pituitary-adrenal axis and its relationship with central respiratory dysfunction in children with prader-willi syndrome\u2019.","volume":"10","author":"Beauloye","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2527261","article-title":"Suicidality and self-harming behaviors in patients with Prader-Willi syndrome: Case report and literature review.","volume":"11","author":"Bellman","year":"2021","journal-title":"Case Rep. Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1542\/peds.113.3.565","article-title":"Behavioral differences among subjects with Prader-Willi syndrome and type I or type II deletion and maternal disomy.","volume":"3","author":"Butler","year":"2004","journal-title":"Pediatrics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2174\/1573396315666190716120925","article-title":"\u2018Prader-willi syndrome - clinical genetics, diagnosis and treatment approaches: An update\u2019.","volume":"15","author":"Butler","year":"2019","journal-title":"Curr. Pediatr. Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/gim.0b013e31822bead0","article-title":"\u2018Prader-willi syndrome\u2019.","volume":"14","author":"Cassidy","year":"2012","journal-title":"Genet. Med."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4161\/rdis.24421","article-title":"\u2018Leptin signaling defects in a mouse model of prader-willi syndrome\u2019.","volume":"1","author":"Colmers","year":"2013","journal-title":"Rare Dis."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0597-0","article-title":"\u2018Effect of topiramate on eating behaviours in prader-willi syndrome: TOPRADER double-blind randomised placebo-controlled study\u2019.","volume":"9","author":"Consoli","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/jne.12994","article-title":"Hypothalamic neuropeptides and neurocircuitries in prader willi syndrome.","volume":"33","author":"Correa-da-Silva","year":"2021","journal-title":"J. Neuroendocrinol."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02470-y","article-title":"\u2018Aripiprazole treatment for temper outbursts in prader-willi syndrome\u2019.","volume":"17","author":"Deest","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2165\/00023210-200317030-00003","article-title":"\u2018Psychiatric disorders in prader-willi syndrome: Epidemiology and management\u2019.","volume":"17","author":"Dykens","year":"2003","journal-title":"CNS Drugs"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.9740\/mhc.2017.01.007","article-title":"Topiramate in the treatment of Prader-Willi syndrome: a case report.","volume":"7","author":"East","year":"2018","journal-title":"Ment. Health Clin."},{"key":"B13","doi-asserted-by":"publisher","first-page":"873","DOI":"10.2147\/TCRM.S70068","article-title":"\u2018Growth hormone therapy for prader\u2013willi syndrome: Challenges and solutions\u2019.","volume":"12","author":"Grugni","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"key":"B14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.endinu.2019.03.004","article-title":"\u2018Psychopathological disorders in prader-willi syndrome\u2019.","volume":"66","author":"Guinovart","year":"2019","journal-title":"Endocrinol. Diabetes Nutr."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.5.e92","article-title":"\u2018The changing purpose of prader-willi syndrome clinical diagnostic criteria and proposed revised criteria\u2019.","volume":"108","author":"Gunay-Aygun","year":"2001","journal-title":"Pediatrics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/20451253211046765","article-title":"\u2018Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: A 12-week open-label trial\u2019.","volume":"11","author":"Gupta","year":"2021","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/bs.podrm.2018.11.005","article-title":"\u2018Topiramate: Comprehensive profile\u2019.","volume":"44","author":"Khalil","year":"2019","journal-title":"Profiles Drug Subst. Excip. Relat. Methodol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.6065\/apem.2013.18.4.161","article-title":"\u2018Pathophysiology and clinical characteristics of hypothalamic obesity in children and adolescents\u2019.","volume":"18","author":"Kim","year":"2013","journal-title":"Ann. Pediatr. Endocrinol. Metab."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/j.1469-7610.2005.01520.x","article-title":"\u2018Prader-willi syndrome: Intellectual abilities and behavioural features by genetic subtype\u2019.","volume":"46","author":"Milner","year":"2005","journal-title":"J. Child Psychol. Psychiatry Allied Discip."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052705","article-title":"\u2018Prader\u2013willi syndrome and hypogonadism: A review article\u2019.","volume":"22","author":"Noordam","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1530\/EC-22-0373","article-title":"The transition from pediatric to adult care in individuals with prader-willi syndrome.","volume":"12","author":"Poitou","year":"2023","journal-title":"Endocr. Connect."},{"key":"B22","author":"Postel-Vinay","year":"2006","journal-title":"Prise en charge des maladies g\u00e9n\u00e9tiques. \u2018Chapitre?: Syndrome de Prader-Willi (SPW)\u2019 Editions Doin."},{"key":"B23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41380-020-00917-x","article-title":"\u2018What can we learn from PWS and SNORD116 Genes about the pathophysiology of addictive disorders?\u2019.","volume":"26","author":"Salles","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.mcna.2017.08.010","article-title":"\u2018Obesity pharmacotherapy\u2019.","volume":"102","author":"Saunders","year":"2018","journal-title":"Med. Clin. North Am."},{"key":"B25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1017\/S1461145702002833","article-title":"\u2018Topiramate attenuates self-injurious behaviour in prader-willi syndrome\u2019.","volume":"5","author":"Shapira","year":"2002","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1352\/0895-80172004109<301:EOTIAW<2.0.CO;2","article-title":"Effects of topiramate in adults with Prader-Willi syndrome.","volume":"4","author":"Shapira","year":"2004","journal-title":"Am. J. Ment. Retard."},{"key":"B27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.eurpsy.2017.03.007","article-title":"\u2018Psychiatric disorders in a cohort of individuals with prader-willi syndrome\u2019.","volume":"44","author":"Shriki-Tal","year":"2017","journal-title":"Eur. Psychiatry J. Assoc. Eur. Psychiatr."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.ridd.2011.02.027","article-title":"\u2018Psychiatric illness in a cohort of adults with prader-willi syndrome\u2019.","volume":"32","author":"Sinnema","year":"2011","journal-title":"Res. Dev. Disabil."},{"key":"B29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/s0887-8994(02)00490-3","article-title":"\u2018Topiramate effectiveness in prader-willi syndrome\u2019.","volume":"28","author":"Smathers","year":"2003","journal-title":"Pediatr. Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1345\/aph.1R501","article-title":"Phentermine\/topiramate for the treatment of obesity.","volume":"3","author":"Smith","year":"2016","journal-title":"Ann. Pharmacother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5603\/EP.a2021.0110","article-title":"\u2018The effect of aripiprazole on leptin levels of patients with chronic schizophrenia and a comparison of leptin, acute phase protein, and cytokine levels with regard to body mass and body composition indexes\u2019.","volume":"73","author":"Sobi\u015b","year":"2022","journal-title":"Endokrynol. Pol."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107939","article-title":"\u2018Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review\u2019.","volume":"118","author":"Steinhoff","year":"2021","journal-title":"Epilepsy Behav."},{"key":"B33","first-page":"432","article-title":"\u2018[Psychiatric disorders in adults with prader-willi syndrome: A systematic literature review]\u2019.","volume":"63","author":"Tarsimi","year":"2021","journal-title":"Tijdschr. Psychiatr."},{"key":"B34","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/B978-0-12-820683-6.00026-9","article-title":"Chapter 26 - prader\u2013willi syndrome: Hormone therapies","author":"Tauber","year":"2021","journal-title":"The human hypothalamus"},{"key":"B35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S2213-8587(21)00002-4","article-title":"\u2018Endocrine disorders in prader-willi syndrome: A model to understand and treat hypothalamic dysfunction\u2019.","volume":"9","author":"Tauber","year":"2021","journal-title":"Lancet Diabtes Endocrinol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1399-0004.2005.00377.x","article-title":"Impact of molecular mechanisms, including deletion size, on Prader-Willi syndrome phenotype: study of 75 patients.","volume":"1","author":"Varela","year":"2005","journal-title":"Clin. Genet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.neubiorev.2018.10.006","article-title":"\u2018A review of psychiatric conceptions of mental and behavioural disorders in prader-willi syndrome\u2019.","volume":"95","author":"Whittington","year":"2018","journal-title":"Neurosci. Biobehav. Rev."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-022-01319-1","article-title":"\u2018Genetic subtypes and phenotypic characteristics of 110 patients with prader-willi syndrome\u2019.","volume":"48","author":"Zhang","year":"2022","journal-title":"Ital. J. Pediatr."}],"updated-by":[{"DOI":"10.3389\/fnins.2023.1189154","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000}}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2023.1126970\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T08:03:20Z","timestamp":1680249800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2023.1126970\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":38,"alternative-id":["10.3389\/fnins.2023.1126970"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2023.1126970","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,6]]},"article-number":"1126970"}}